ClinicalTrials.gg
CompletedNCT06701747Updated Nov 22, 2024

A Nomogram Predicting the Risk of High-dose Transfusion in Non-cardiac Surgery

An observational study in Massive Transfusion and Nomogram Model, sponsored by West China Hospital. Completed at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by West China Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
11,197
Ages
14 Years and older
Sex
All
01

Study summary

This retrospective study was designed to develop a preoperative nomogram, validated both internally and externally, to supply an individual and precise tool for predicting the probability that patients will require perioperative transfusion therapy.

Read the detailed description

Perioperative red blood cells (RBCs) transfusion is a necessary guarantee for surgical surgery and one of the indispensable means in modern medical treatment. In recent years, with the continuous improvement of medical standards, various major and complex surgeries have been carried out. The total number of patients receiving surgical treatment increased year by year, and the demand for surgical blood has also increased rapidly. Although unpaid blood donation has been vigorously advocated in recent years, the supply of blood products are still difficult to meet the growing demand for clinical blood. RBCs transfusion is often associated with unavoidable complications such as anaphylaxis and transfusion-related acute lung injury, which may lead to delayed recovery, increased hospital stay and medical costs, and result in serious adverse effects and even death.

Hemorrhage is a common complication of surgery. The effect of blood transfusion treatment and the patient's recovery process will be affected by the amount of blood transfused during the perioperative period. Similarly, blood products that are prepared in advance for surgery often remains unused perioperatively, leading to the waste of valuable blood resources and an increase in hospital expenses. Hemorrhage is one of the leading causes of death in various clinical situations, such as severe trauma, heart surgery, and traffic accidents.Timely and effective high-dose transfusion is directly related to life and death. However, high-dose transfusion may also lead to dilution coagulopathy, increased risk of bleeding, and imbalance in the internal environment.

In brief, there is an urgent requirement for a systematic, evidence-driven tool to comprehensively weigh the risks and benefits of high-dose RBCs transfusion in clinical practice.

02

Conditions studied

  • Massive Transfusion
  • Nomogram Model

Keywords

  • Massive transfusion
  • Red blood cells
  • Nomogram
  • Non-cardiac surgery
  • Patient blood management
03

In context

Lead sponsor

West China Hospital is the lead sponsor of 498 studies on the registry; 244 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This retrospective study included 【】patients who received RBCs transfusion during non-cardiac surgery at West China Hospital between January 2018 and June 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing non-cardiac surgery during hospitalization.
  • Patients receiving allogeneic RBCs transfusion within 24 hours during and after surgery.

Exclusion criteria

Exclusion Criteria:

  • Age under 15 years.
  • Patients with incomplete clinical data.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
11,197 participants (actual)
Patient registry
No

Groups and cohorts

  • High-dose group

    Receive RBCs transfusion over 1600mL

  • No-high-dose group

    Receive RBCs transfusion under 1600mL

06

What researchers measure

Primary outcomes

  1. RBCs transfusion volume

    The total volume of RBCs transfused within 24 from the start of transfusion.

    Time frame: Up to 24 hours after transfusion

07

Study locations

1 site
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in May 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 22, 2024
StartActual
Sep 1, 2023
Primary completionActual
May 1, 2024
CompletionActual
Jul 31, 2024
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06701747
Responsible party
Ren Liao (Associate professor, West China Hospital) — Principal investigator
First posted
Nov 22, 2024
Start date
Sep 1, 2023
Primary completion
May 1, 2024
Completion
Jul 31, 2024
Last update
Nov 22, 2024

Study contacts

Ren Liao, M.D.
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion